• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aclarion Inc. filed SEC Form 8-K: Other Events

    3/13/25 10:31:56 AM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    Aclarion, Inc. 8-K
    false 0001635077 0001635077 2025-03-13 2025-03-13 0001635077 ACON:CommonStockParValue0.00001PerShareMember 2025-03-13 2025-03-13 0001635077 ACON:WarrantsEachExercisableForOneShareOfCommonStockMember 2025-03-13 2025-03-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 13, 2025

     

     

     

    Aclarion, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 001-41358 47-3324725
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

     

    8181 Arista Place, Suite 100  
    Broomfield, Colorado 80021
    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (833) 275-2266

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

      Trading  
    Title of each class Symbol(s) Name of each exchange on which registered
    Common Stock ACON Nasdaq Stock Market
    Common Stock Warrants ACONW Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 8.01 Other Events.

     

    As previously disclosed, Aclarion, Inc., a Delaware corporation (the “Company”) has completed several financing transactions in the first quarter of 2025.

     

    As a result of these transactions, the Company has a current cash balance of approximately $15.2 million. The Company is now in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain at least $2,500,000 in stockholders’ equity.

     

    As previously disclosed, on March 5, 2025, the Company's stockholders approved, among other things, the issuance of the common shares underlying the Company's Series A and Series B warrants which we publicly offered on January 15, 2025. The Series A and Series B warrants became exercisable when the favorable stockholder vote was obtained.

     

    Since March 6, 2025, holders of Series B warrants have exercised approximately 87% of our outstanding Series B warrants using the alternative cashless exercise ("ACE") feature included in those warrants. The Company has issued approximately 12.7 million common shares in such Series B warrant exercises.

     

    The Company has approximately 13.7 million total shares outstanding as of March 12, 2025.

     

    To date, none of the Series A warrants have been exercised. The exercise price of the Series A warrants has been adjusted (after giving effect to our 1-335 reverse stock split effective January 30, 2025) in accordance with their terms to the "floor price" equal to $6.70 per common share ($0.02 floor price prior to such reverse stock split). Such $6.70 exercise price is higher than the current market price of the Company’s common stock. The Series A warrants do not contain the alternative cashless exercise ("ACE") feature contained in the Series B warrants.

     

    As previously disclosed, at our special stockholders’ meeting on September 23, 2024, our stockholders approved a proposal to grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our Common Stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by stockholders.

     

    We may implement a reverse stock split in the future, which could assist with the Company’s ongoing compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a $1.00 minimum bid price.

     

     

     

     

     2 

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ACLARION, INC.
         

    March 13, 2025

    By:/s/ John Lorbiecki
      Name: John Lorbiecki
      Title: Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     3 

    Get the next $ACON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

      USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location

      5/20/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

      Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back

      5/12/25 7:34:07 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Welcomes Advocate Health as CLARITY Trial Site

      Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

      5/5/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thramann Jeffrey John

      4 - Aclarion, Inc. (0001635077) (Issuer)

      3/28/23 8:30:04 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

      4 - Aclarion, Inc. (0001635077) (Issuer)

      2/21/23 4:02:40 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

      4 - Aclarion, Inc. (0001635077) (Issuer)

      12/29/22 7:57:11 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      11/13/24 3:06:29 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Aclarion Inc.

      SC 13G - Aclarion, Inc. (0001635077) (Subject)

      9/5/24 4:19:39 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      3/29/24 5:00:57 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    See more

    $ACON
    SEC Filings

    See more
    • Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

      CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

      8/29/24 6:57:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

      Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

      5/2/23 7:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

      Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

      1/17/23 8:29:31 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Aclarion Inc.

      10-Q - Aclarion, Inc. (0001635077) (Filer)

      5/15/25 7:54:10 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Aclarion Inc.

      DEF 14A - Aclarion, Inc. (0001635077) (Filer)

      5/12/25 8:27:41 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Aclarion Inc.

      EFFECT - Aclarion, Inc. (0001635077) (Filer)

      5/6/25 12:15:15 AM ET
      $ACON
      Medical Specialities
      Health Care